| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
Vitamin D receptor (VDR). ZK159222 binds to VDR with high affinity but fails to induce the conformational changes necessary for coactivator recruitment. By stabilizing an inactive VDR conformation, it prevents the interaction of VDR with coactivator proteins and blocks 1α,25(OH)₂D₃-induced transcriptional activation. This results in functional antagonism of vitamin D signaling.
|
|---|---|
| ln Vitro |
ZK159222 is classified as a weak VDR agonist because it requires concentrations of approximately 7 times higher than the natural hormone 1α,25-(OH)2D3 to stabilize the formation of the VDR-RXR heterodimer complex on the DR3-type VDRE. This means that ZK159222 is part of the class of 1α,25-(OH)2D3 analogs that stabilize the formation of an additional third functional VDR conformation, which has also been described for some agonistic 20-epi analogs. When 1 μM ZK159222 is co-treated with 10 nM 1α,25-(OH)2D3, the residual reporter gene activity that results is nearly identical to the partial agonistic activity of 1 μM ZK159222 [1].
ZK159222 shows similar potency and sensitivity to 1α,25(OH)₂D₃ in ligand-dependent gel shift assays using VDR, RXR, and specific DNA binding sites. It inhibits the differentiation of HL60 cells in the presence of 1,25-(OH)₂D₃ at a concentration of 6 nM. ZK159222 demonstrates functional antagonism in reporter gene assays in HeLa and MCF-7 cells. |
| ln Vivo |
In vivo, ZK159222 would be expected to modulate vitamin D signaling and exhibit anti-inflammatory effects. Studies on ZK159222 and its analog ZK191784 showed anti-inflammatory properties in macrophage-induced preadipocytes by modulating NF-κB and MAPK signaling. These effects suggest potential for treating metabolic inflammation.
|
| Enzyme Assay |
VDR binding assays use recombinant VDR and a radiolabeled ligand, such as [3H]-1α,25(OH)₂D₃. ZK159222 competes with the radioligand for binding to VDR. The reaction is incubated at 4°C, and bound radioactivity is separated by charcoal-dextran adsorption and counted by scintillation.
|
| Cell Assay |
In vitro cell assays for ZK159222 include reporter gene assays in HeLa and MCF-7 cells to assess VDR antagonism. HL60 cell differentiation is measured by nitroblue tetrazolium reduction or flow cytometry. Anti-inflammatory effects are assessed by measuring IL-6 and TNF-α secretion in macrophage-induced preadipocytes by ELISA.
|
| Animal Protocol |
In vivo animal protocols for ZK159222 would use rodent models of inflammation or metabolic disease. The compound is administered intraperitoneally or orally. Inflammatory cytokine levels are measured in plasma and tissues. Metabolic parameters such as insulin sensitivity and adipose tissue inflammation are assessed.
|
| References | |
| Additional Infomation |
ZK 159222 is a type of vitamin D.
|
| Molecular Formula |
C32H48O5
|
|---|---|
| Molecular Weight |
512.73
|
| Exact Mass |
512.35
|
| CAS # |
156965-15-0
|
| Related CAS # |
156965-15-0
|
| PubChem CID |
9936230
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
646.3±55.0 °C at 760 mmHg
|
| Flash Point |
201.1±25.0 °C
|
| Vapour Pressure |
0.0±4.4 mmHg at 25°C
|
| Index of Refraction |
1.568
|
| LogP |
6.46
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
37
|
| Complexity |
941
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
CCCCOC(=O)C1(CC1)[C@@H](/C=C/[C@@H](C)[C@H]2CC[C@@H]\3[C@@]2(CCC/C3=C\C=C/4\C[C@H](C[C@@H](C4=C)O)O)C)O
|
| InChi Key |
SPARTCPUGRJFRS-PBDCIXLPSA-N
|
| InChi Code |
InChI=1S/C32H48O5/c1-5-6-18-37-30(36)32(16-17-32)29(35)14-9-21(2)26-12-13-27-23(8-7-15-31(26,27)4)10-11-24-19-25(33)20-28(34)22(24)3/h9-11,14,21,25-29,33-35H,3,5-8,12-13,15-20H2,1-2,4H3/b14-9+,23-10+,24-11-/t21-,25-,26-,27+,28+,29-,31-/m1/s1 SMILES
|
| Chemical Name |
butyl 1-[(E,1R,4R)-4-[(1R,3aS,4E,7aR)-4-[(2Z)-2-[(3S,5R)-3,5-dihydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-1-hydroxypent-2-enyl]cyclopropane-1-carboxylate
|
| Synonyms |
ZK159222 ZK 159222 ZK-159222.
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~195.04 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.88 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.88 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9503 mL | 9.7517 mL | 19.5034 mL | |
| 5 mM | 0.3901 mL | 1.9503 mL | 3.9007 mL | |
| 10 mM | 0.1950 mL | 0.9752 mL | 1.9503 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA